DOse REduction of preoperatieve radiotherapyin MYxoid liposarcoma.(Dosis verlaging van de preoperatieve bestraling van myxoidliposarcomen).

DOse REduction of preoperatieve radiotherapyin MYxoid liposarcoma.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON23428

Enrollment

Registered

2010-11-05

Start date

2011-01-01

Completion date

Unknown

Last updated

2025-03-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

radiotherapy, myxoid liposarcoma, soft tissue sarcoma (radiotherapie, myxoid sarcomm en weke delen sarcoom)

Interventions

To study whether a dose reduction of preoperative radiotherapy in MLS from 50Gy to 36Gy is equally effective in inducing extensive necrosis (thus maintaining comparable clinicopathological responses).

Eligibility

Inclusion criteria

Inclusion criteria: 1. Age >18 years; 2. By biopsy proven myxoid sarcoma; 3. Performance score ECOG 0-2.

Exclusion criteria

Exclusion criteria: 1. Prior radiotherapy to target area; 2. Anticoagulant medication of any kind; especially Ascal (and derivates), coumarines, all heparin and heparin-like formulations; 3. Pregnancy.

Design outcomes

Primary

Measure	Time frame
The dose reduction will be regarded as a success if at least 90% of thus treated patients show at least 90% necrosis in the definitive resection specimen.	—

Secondary

Measure	Time frame
The aim is to provide a stopping rule for inefficacy of the new dose.	—

Contacts

Public ContactR.L.M. Haas

Plesmanlaan 121

r.haas@nki.nl+31 (0)20 512 9111

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)